-
-
-
-
-
-
-
Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion
-
-
-
-
-
-
-
Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M
-
-
-
-
-
-
-
Harmony Biosciences (HRMY) Announces Favorable Settlement in ANDA Litigation
-
-
-
-
-
-
-
Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs
-
-
-
-
-
-
-
Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028
-
-
-
-
-
-
-
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $52 at Needham
-
-
-
-
-
-
-
HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME
-
1,168,813 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

